03:45 AM EDT, 10/14/2026 (MT Newswires) -- Physiomics (PYC.L) secured a contract worth 119,000 pounds sterling to deliver model-informed drug development modelling. The London-listed mathematical modelling, data science and biostatistics company said Wednesday that it will incorporate pharmacokinetic/pharmacodynamic modeling in its deliverables under the contract. Meanwhile, Physiomics also disclosed that it agreed to explore further commercialization of its personalized dosing software and associated intellectual property under recently signed non-binding heads of terms with an unnamed third party. The parties will explore the introduction of the software to new markets, including the US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.